MarketersMEDIA Newsroom

Creative Biolabs Empowers Researchers to Overcome Hurdles in Complement Drug Development

Creative Biolabs has expanded its complement testing capabilities to help researchers overcome challenges in complement drug development through comprehensive complement activity assays, CH50 ...
FOX8 Cleveland

NovelMed Phase I Clinical Trial Shows Inhibition of the Alternative Pathway and Preservation of the Classical Pathway – A Long-Acting Anti-Properdin Monoclonal Antibody ...

Phase I Clinical Trial in healthy subjects shows that NM3086 was safe and well tolerated at all doses (0.1 to 20 mg/kg) in six cohorts. Total AP inhibition was achieved through all cohorts and the ...
Nasdaq

Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway

Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity ANX1502 Generally Well Tolerated Across ...
MedPage Today

Alternative Pathway Inhibition Makes Good in IgA Nephropathy

SAN DIEGO -- There was a clinically meaningful reduction in proteinuria with iptacopan (Fabhalta), and a confirmed clinical benefit of alternative pathway inhibition, in a rare kidney disorder, ...
The American Journal of Managed Care

Type 1 Diabetes Onset Tied to Decreased Complement Protein Levels

These findings suggest complement protein levels may be an important biomarker for type 1 diabetes. Disruption of the complement system appears to precede the onset of islet autoimmunity (IA), making ...